ArticleCureus2025
Prevalence of Diabetic Retinopathy Among Patients With Diabetes and Its Correlation With Inflammatory Marker Levels in Tear Fluid.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Diabetic retinopathy (DR) is a leading microvascular complication of diabetes mellitus (DM) and a primary cause of vision loss worldwide. Markers such as NF-κB, TNF-α, and IL-6 have been proposed as potential early indicators on the basis of Inflammation playing a critical role in DR pathogenesis. This study aimed to determine the prevalence of DR among asymptomatic diabetic patients and evaluate correlations between tear fluid inflammatory markers and DR severity. Methods A cross-sectional observational study was conducted over two months at a tertiary care hospital in Kerala, India. Although an initial target of 120 participants was set, logistical and technical challenges in tear sample isolation limited recruitment to 50 asymptomatic diabetic patients. Fundus images were captured using a non-mydriatic handheld fundoscopy device with artificial intelligence (AI)-assisted grading of DR. Tear fluid samples, collected using Schirmer paper, were analysed for nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (NF-α), and interleukin-6 (IL-6) via reverse transcription polymerase chain reaction (RT-PCR). Patient demographics, diabetes duration, comorbidities, and treatment history were documented. Associations between the presence of DR, clinical variables, and tear marker levels were analysed. Results DR was detected in 38% of participants, predominantly among patients aged >60 years and with longer diabetes duration. Insulin use and disease duration were significantly associated with DR, while age, gender, and oral antidiabetic use were not. Tear fluid inflammatory markers did not show a significant correlation with DR status. NF-κB was undetectable, and TNF-α and IL-6 levels were inconsistently elevated in DR-positive patients. Methodological factors, including tear sample over-dilution in 2 mL universal transport medium (UTM) and ocular surface conditions, likely contributed to these findings. Conclusion DR prevalence among asymptomatic diabetic patients is high, underscoring the importance of routine retinal screening. Non-mydriatic AI-assisted fundus imaging is an effective and practical tool for early detection. Tear fluid inflammatory markers, as measured in this study, were not predictive of DR, likely due to sample collection and amplification limitations. Future studies optimizing tear collection and RNA stabilization may establish reliable non-invasive biomarker-based screening, enabling earlier intervention and reducing vision-related morbidity in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.